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Spermatogenic cellsDehydroepiandrosterone sulfate (DHEAS) is a circulating steroid produced in the adrenal cortex, brain, and go-
nads. Whereas a series of investigations attest to neuroprotective effects of the steroid in the brain, surprisingly
little is knownabout the physiological effects of DHEAS on cells of the reproductive system. Herewe demonstrate
that DHEAS acting on the spermatogenic cell line GC-2 induces a time- and concentration-dependent phosphor-
ylation of c-Src and Erk1/2 and activates the transcription factors activating transforming factor-1 (ATF-1) and
cyclic AMP-responsive element binding protein (CREB). These actions are consistent with the non-classical sig-
naling pathway of testosterone and suggest that DHEAS is a pro-androgen that is converted into testosterone
in order to exert its biological activity. The fact, however, that steroid sulfatase mRNA was not detected in the
GC-2 cells and the clear demonstration of DHEAS-induced activation of Erk1/2, ATF-1 and CREB after silencing
the androgen receptor by small interfering RNA (siRNA) clearly contradict this assumption and make it appear
unlikely that DHEAS has to be converted in the cytosol into a different steroid in order to activate the kinases
and transcription factors mentioned. Instead, it is likely that the DHEAS-induced signaling is mediated through
the interaction of the steroid with a membrane-bound G-protein-coupled receptor, since silencing of Guanine
nucleotide-binding protein subunit alpha-11 (Gnα11) leads to the abolition of the DHEAS-induced stimulation
of Erk1/2, ATF-1, and CREB. The investigation presented here shows a hormone-like activity of DHEAS on a sper-
matogenic cell line. Since DHEAS is produced in male and female reproductive organs, these ﬁndings could help
to deﬁne new roles for DHEAS in the physiology of reproduction.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Dehydroepiandrosterone (DHEA) is mainly produced by the adrenal
zona reticularis and is almost entirely converted by the enzyme
sulfotransferase to dehydroepiandrosterone sulfate (DHEAS), which is
then secreted into the serum [1]. DHEAS is the most abundant circulat-
ing steroid. Its concentration in plasma is between 1.3 and 6.8 μM,
which is approximately 200-fold higher than the plasma concentrations
of DHEA (7–31 nM) [2].
While sulfated steroids have long been considered to be biologically
inactive waste products of steroid hormone metabolism, the discovery
of cytosolic steroid sulfatase prompted the new idea that the sulfates
constitute a reservoir that upon desulfation can deliver precursors for
steroid hormone synthesis. Thus, DHEAS has been viewed as a pro-
androgen that, after being transported into cells, becomes desulfated
by steroid sulfatase to DHEA and further converted into testosteronegie und -Biochemie, Fachbereich
urter Str. 100, D-35392 Giessen,
giessen.de (G. Scheiner-Bobis).
ights reserved.or other steroid hormones in order to exert its biological activity [3].
DHEA andDHEAS are also produced in the brain [4], where their biolog-
ical activity is considered to be neuroprotection [5].
Numerous recent investigations demonstrate DHEAS-speciﬁc effects
that are distinct from effects induced byDHEA, indicating that desulfation
and conversion of DHEAS to other steroid hormones are not prerequisites
for its actions and suggesting that caution should be used in interpreting
the actions of either of the steroids. Thus, 1 μMDHEASwas shown to in-
hibit nerve growth factor (NGF)-induced proliferation of pheochromo-
cytoma PC12 cells and to stimulate chromogranin A expression and
catecholamine release from NGF-treated cells [6,7]. Similarly, DHEAS
was shown to speciﬁcally stimulate growth factor-induced proliferation
of bovine chromafﬁn cells in an age-dependentmanner [8]. In the same
investigation DHEA decreased the proliferative effect of the growth fac-
tors, indicating that the cellular responses to DHEA and DHEAS are me-
diated via different receptors [8]. Concerning their neuroprotective
effects [5], DHEA andDHEASmight act by triggering different pathways.
Thus, DHEA, but not DHEAS, prevented neurotoxicity induced by N-
methyl-D-aspartate (NMDA) by inhibiting the NMDA-induced activa-
tion of Ca2+-sensitive nitric oxide (NO) synthase and NO production
[9]. In contrast, the neuroprotective effects of DHEAS against NMDA-
Table 1
Antisera used and their providers (IF = immunoﬂuorescence; WB = western blot).
Antibody Catalog no. Provider Address
Anti-AR (H-280)
(for IF)
sc-13062 Santa Cruz
Biotechnology, Inc
Heidelberg, Germany
Anti-phospho-CREB and
anti-phospho-ATF-1
(for WB)
4276 Cell Signaling
Technology
Frankfurt amMain,
Germany
Anti-phospho-CREB
(for IF)
9198 Cell Signaling
Technology
Frankfurt amMain,
Germany
Anti-phosho-Erk1/2
(for WB and IF)
4370 Cell Signaling
Technology
Frankfurt amMain,
Germany
Anti-phospho-c-Src
(for WB)
4276 Cell Signaling
Technology
Frankfurt amMain,
Germany
Anti-total Erk1/2
(for WB)
9102 Cell Signaling
Technology
Frankfurt amMain,
Germany
Anti-pan-Actin
(for WB)
4968 Cell Signaling
Technology
Frankfurt amMain,
Germany
Anti-phospho-ATF-1
(for IF)
2456-1 Epitomics Burlingame, USA
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ceptor [9].
All of the above information indicates a role for DHEAS that is differ-
ent from that of DHEA. Taking into consideration that DHEA and DHEAS
are produced not only in the adrenal cortex and brain but also in the go-
nads [10–12], it is rather surprising that very little is known about the
effects of DHEAS on the cells of the male or female reproductive sys-
tems. Thus, in order to investigate a possible biological signiﬁcance of
DHEAS in cells of the reproductive system we analyzed its effects on
the spermatogenic cell line GC-2 spd (ts). The results obtained here re-
veal new aspects of DHEAS action and will possibly provide new in-
sights into DHEAS-mediated physiological mechanisms associated
with fertility and reproduction.
2. Materials and methods
2.1. Cell culture
The spermatogenic cell line GC-2 spd (ts) [13] (hereafter referred
to as GC-2) was cultured as recommended in DMEM (TS) high glucose
(PAA Laboratories GmbH, Pasching, Austria) supplemented with
10% fetal calf serum (FCS), 1% penicillin/streptomycin combination
(100 U/ml of each) and 1% L-glutamine. Cells were incubated in a hu-
midiﬁed incubator at 31 °C under 5% CO2. The medium was renewed
every two days. Experiments were carried out after the 20th day of
culture (the third passage).
2.2. Cell lysates
GC-2 cellswere seeded at a density of 105 cells in 5-cmculture dishes
and grown as described above until they reached 70–80% conﬂuence.
Cells were then incubated for 24 h with 1% FCS. Various concentrations
of DHEAS dissolved in ethanol were added to the cells and incubation
was continued for various times (seeﬁgure legends for details). The con-
centration of ethanol was identical in all samples. Themediumwas then
removed by aspiration and cells were washed twice with ice-cold
phosphate-buffered saline (PBS; without Ca2+ or Mg2+; PAA Laborato-
ries GmbH) and lysed in 400 μl of a commercially available cell lysis
buffer (Cell Signaling Technology, Frankfurt, Germany) according to
the protocol of the provider. Immediately before use, 1 μM PMSF, 1×
protease inhibitor cocktail (Roche, Mannheim, Germany) and 2 μg/ml
pepstatin were added to the lysis buffer. All lysis steps were carried
out on ice. After 10 min of incubation cells were harvestedwith a scrap-
er, transferred into vials, and sonicated 5 times for 5 s, with intervals of
2 s. The reaction vials were then centrifuged at 13,000 ×g for 20 min at
4 °C. Theprotein content of the supernatantswas determined at 540 nm
using the bicinchoninic acid (BCA) protein assay reagent kit (Pierce,
Rockford, IL, USA) and a Labsystems (Helsinki, Finland) plate reader.
The lysis buffer was included in the bovine serum albumin protein stan-
dard. Aliquots of the supernatant taken for further analysis were stored
at−20 °C.
2.3. SDS-PAGE and western blotting
A total of 10 μg protein from cell lysateswas separated by SDS-PAGE
on slab gels containing 10% acrylamide and 0.3% N,N′-methylene-bis-
acrylamide. Biotinylated molecular weight markers (Cell Signaling
Technology) were used to determine the relative molecular mass of
the separated proteins. After electrophoresis proteins were blotted
onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany)
for 30 min at 200 mA. Desired protein bands were visualized by incu-
bating the membranes according to the protocol of the providers of
the primary antibody (Table 1) and the appropriate secondary antibody
of the enhanced chemiluminescence kit (ECL; GE HealthCare, Munich,
Germany). For the simultaneous detection of phospho-CREB and
phospho-ATF-1, western blots were probed with an antibody thatcross-reacts with the two phosphorylated proteins (Cell Signaling
Technology). Horseradish peroxidase-conjugated anti-biotin IgG (Cell
Signaling Technology) at a dilution of 1:2000 was included in the
mixture containing the secondary antibody in order to detect the
biotinylated molecular weight marker.
The chemiluminescence obtained was visualized by exposure to
ﬁlm. Films were analyzed by the TotalLab gel image analysis software
(Biostep, Jahnsdorf, Germany).
2.4. Detection of speciﬁc mRNA/cDNA for steroid sulfatase, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), androgen receptor (AR), and guanine
nucleotide binding protein, alpha 11 (Gnα11) by RT-PCR
Total mRNA was isolated from GC-2 cells by following the proto-
col of the commercially available RNeasy Mini Kit (Qiagen, Hilden,
Germany). Reverse transcription and PCR ampliﬁcation of steroid
sulfatase-speciﬁc mRNA/cDNA were carried out by the Reverse Tran-
scription System(Promega,Mannheim, Germany) according to the pro-
tocol of the provider. For PCR ampliﬁcation a total of 10 ng/μl of cDNA
was incubated with 20 pmol/ml of each primer, 10 mM Tris HCl,
50 mM KCl, 1–2.5 mMMgCl2, 1 mM dNTPs and 2 units Taq DNA poly-
merase. The ﬁnal volume of the solutions was 25 μl. PCR was carried
out in a MasterCycler Gradient (Eppendorf, Hamburg, Germany). Sam-
ples were incubated at 95 °C for 5 min, followed by 40 cycles of dena-
turation at 95 °C for 30 s, annealing at temperatures ranging between
60 and 62 °C for 1 min, and cDNA extension at 72 °C for 1 min. After
ampliﬁcation, a ﬁnal extension at 72 °C was performed for 10 min.
The forward primer was the oligonucleotide 5′ACTGCTTCCTCATG
GACGACCTC3′ and the reverse primer was 5′AGGCGTTGCAGTAGTG
GAACAGG3′. These amplify a region between bases 1001 and 1624 of
mouse steroid sulfatase-speciﬁc mRNA and yield an ampliﬁcate of
624 bp.
GAPDH-speciﬁc mRNA/cDNA was detected using a similar protocol
with the exceptions that the annealing temperature was kept constant
at 54 °C, the extension time was 45 s, and the MgCl2 concentration was
2.5 mM. The forward primer was the oligonucleotide 5′GGAGATTGTTGC
CATCAACG3′ and the reverse primer 5′CACAATGCCAAAGTTGTCA3′.
These amplify a fragment of 430 bp between bases 128 and 557 of
mouse GAPDH-speciﬁc mRNA.
AR-speciﬁc mRNA/cDNA was ampliﬁed under the same conditions
used for the ampliﬁcation of GAPDH. Forward and reverse primers
were the oligonucleotides 5′AGCGCAATGCCGCTATGGGG3′ and 5′GTG
GGGCTGCCAGCATTGGA3′, respectively. These amplify a 708-bp frag-
ment of mouse AR-speciﬁc mRNA localized between bases 1220 and
1927.
Gnα11-speciﬁc mRNA/cDNA was ampliﬁed under the same condi-
tions asGAPDH. Forward and reverse primerswere the oligonucleotides
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Fig. 1. Activation of Erk1/2 by DHEAS. Lysates of DHEAS-treated GC-2 cells were run on
SDS-PAGE and subsequently probed in western blots. (A–C) Time-dependent activation
of Erk1/2: While incubation with 1 nM DHEAS had no effect on the amount of total
Erk1/2 (A), it stimulated its phosphorylation (B). Phosphorylation of Erk1/2 (corrected
for the amount of total Erk1/2 as shown in panel A) was signiﬁcant after 30 min of incu-
bation with DHEAS (C) (n = 4; means ± SEM; * = p ≤ 0.05; ** = p ≤ 0.01). (D–E):
Treatment of cells for 30 min with the indicated concentrations of DHEAS had no effect
on total Erk1/2 (D) but led to an increase in phosphorylated Erk1/2 (E). Within this time
frame activation of Erk1/2 (corrected for the amount of total Erk1/2 as shown in panel
D) was signiﬁcant at DHEAS concentrations ≥0.1 nM (C) (n = 5–7; means ± SEM;
* = p ≤ 0.05; ** = p ≤ 0.01).
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in Fig. 1D–E. Detection of total actin served as loading control (A). DHEAS stimulated c-Src
phosphorylation (activation) at Tyr419 (B). Activation was signiﬁcant at DHEAS concen-
trations ≥1 nM (B) (n = 4–5; means ± SEM; * = p ≤ 0.05). Values in panel C were
corrected for differences in loading by standardizing to the amount of total actin detected
in parallel western blots (A).
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Fig. 3. DHEAS-induced activation of ATF-1 and CREB. Conditions were the same as for the
experiments shown in Fig. 1D–E. For the western blot (A) an antibody against phospho-
CREB was used that cross-reacts with phospho-ATF-1 (see “Materials and methods”). Ac-
tivation of ATF-1 (B) or CREB (C) was signiﬁcant at DHEAS concentrations≥0.1 nM (n =
4;means ± SEM; * = p ≤ 0.05). Valueswere corrected for differences in loading by stan-
dardizing to the amount of total actin detected in parallel western blots (as in Fig. 2).
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respectively. These amplify a 917-bp fragment of mouse Gq11-speciﬁc
mRNA localized between bases 70 and 986.
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Cells were incubated as described above with or without 10 nM
DHEAS in the presence or absence of 10 nM STX64 (Sigma-Aldrich,
Taufkirchen, Germany). This concentration of STX64 has been consid-
ered sufﬁcient for complete inactivation of steroid sulfatases [14]. All
samples contained 2 μl DMSO, whichwas the solvent for stock prepara-
tions of STX64. After 30 min of incubation, cell lysates were prepared
as described above. Activated Erk1/2 and total Erk1/2 were detected
after SDS-PAGE and western blotting as stated under “Materials and
methods”, Section 2.3.
2.6. Silencing of the androgen receptor via siRNA
Silencing of the androgen receptor was carried out by using
commercially available siRNA and by following the protocol of theGC-2 cells; sulfatase detection
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Fig. 4.Assessment of the involvement of steroid sulfatase in theDHEAS-induced signaling.
(A) RT-PCR for the detection of steroid sulfatase-speciﬁc mRNA/cDNA. Steroid sulfatase-
speciﬁc mRNA/cDNA was not detectable in GC-2 cell extracts at any annealing tempera-
ture and MgCl2 concentration tested. The expected sulfatase-speciﬁc ampliﬁcate of
624 bpwas clearly detected, however, in extracts frommouse adrenals, indicating the cor-
rect choice of primers. A GAPDH-speciﬁc ampliﬁcate was detected in the GC-2 prepara-
tions, indicating that the reason for not detecting sulfatase-speciﬁc ampliﬁcates in the
GC-2 preparations was not due to the poor quality of the mRNA/cDNA employed. (B)
Western blot demonstrating that the steroid sulfatase-speciﬁc inhibitor STX64 does not
prevent or reduce DHEAS-induced stimulation of Erk1/2. (C) Western blot showing total
Erk1/2 in the same cell lysates used in panel B. (D) DHEAS-induced activation of Erk1/2
in the presence STX64 was highly signiﬁcant (n = 3; means ± SEM; ** = p ≤ 0.01).provider (Stealth™ RNAi; Invitrogen, Karlsruhe, Germany). The oli-
gonucleotides used were: primer pair 1: 5′ACUCGAUCGCAUCAU
UGCAUGCAAA3′ and 5′UUUGCAUGCAAUGAUGCGAUCGAGU3′; primer
pair 2: 5′CCCAGAAGAUGACUGUALJCACACAU3′ and 5′AUGUGUGAUA
CAGUCAUCUUCUGGG3′; and primer pair 3: 5′CCAGAUUCCUUUGCUGC
CUUGUUAU3′ and AUAACAAGGCAGCAAAGGAAUCUGG3′. Control cells
were treated with Opti-MEM plus Lipofectamine 2000 plus Stealth™
RNAi negative control. Transfection efﬁciency was estimated by the
Block-iT™ Transfection Kit (Invitrogen, Karlsruhe, Germany) according
the protocol of the provider. After 72 h of incubation cells were used to
isolate mRNA for RT-PCR (see previous paragraph). A second set of cells
was stimulated with 1 nMDHEAS and used for the detection of activated
Erk1/2, CREB, and ATF-1 by immunoﬂuorescence, as described further
below. Finally, a third set of cells was stimulated with 1 nM DHEAS and
used for the isolation of cell lysates to be investigated in western blots.
2.7. Silencing of the Gnα11 protein via siRNA
Silencing of the Gnα11 protein was carried out by using commer-
cially available siRNA and by following the protocol of the provider
(Silencer® Select siRNA; Invitrogen). The oligonucleotides used were:
primer pair 1: 5′CCAAGUUGGUGUACCAGAAtt3′ and 5′UUCUGGUA
CACCAACUUGGtg′; and primer pair 2: 5′CAAGAUCCUCUACAAGUAUtt3′
and 5′AUACUUGUAGAGGAUCUUGag3′. Control cells were treated with
Opti-MEM plus Lipofectamine 2000 plus the siRNA negative control as
supplied by the provider. All other steps were the same as described
in the previous paragraph.
2.8. Immunoﬂuorescence
GC-2 cells that had been treated with siRNA to silence either AR or
Gα11 were incubated with vehicle alone or vehicle + 1 nM DHEAS for
30 min. The medium was then aspirated and the cells were ﬁxed using
200 μl of ice-cold methanol containing a total of 20 ng of DAPI (4′,6-
diamidino-2-phenylindole). After 15 minof incubation at RT, theDAPI so-
lution was aspirated and slides were allowed to dry for 15 min before
washing 3 times with 500 μl PBS. The cells were then blocked with 10%
FCS and 0.3% Triton-X100 in PBS for 1 h at RT. The ﬁrst antibody
(Table 1), diluted as recommended by the provider, was then added
and incubationwas continued for 2 days at 4 °C in a humidiﬁed chamber.
The antibody against phospho-Erk1/2 was from Cell Signaling Technolo-
gy. The antibody against phospho-ATF-1 was from Epitomics (Burlin-
game, CA, USA). This antibody is phospho-ATF-1 speciﬁc and does not
interact with phospho-CREB. For the speciﬁc detection of phospho-
CREB, an antibody from Cell Signaling Technology was used withG
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Fig. 5. Silencing expression of AR by means of siRNA. GC-2 cells were treated with three
different nucleotide pairs of siRNA against AR according to the manufacturer's protocol.
Control cells were treated with either Opti-MEM alone, Opti-MEM plus Lipofectamine,
or both of the above plus negative control siRNA, provided in the kit of the manufacturer.
Total RNA was then isolated and subjected to RT-PCR to amplify AR-speciﬁc mRNA/cDNA
fragments of 708 bp. Treatment of the cells with siRNA oligo pair 3 abolished the expres-
sion of AR-speciﬁc mRNA/cDNA. This oligo pair was used for the subsequent experiments
depicted in Fig. 6 and 7.
3068 M. Shihan et al. / Biochimica et Biophysica Acta 1833 (2013) 3064–3075negligible interaction with phospho-ATF-1. The antibody against the
androgen receptor was from Santa Cruz Biotechnology (Heidelberg,
Germany).
The slideswere thenwashed 3 times for 5 min eachwith 500 μl PBS.
Staining was achieved by incubating for 20 min at room temperature
with an Alexa Fluor 488-labeled goat anti-rabbit IgG (Invitrogen,
Karlsruhe, Germany; diluted at 1:500 in 2% FCS, 0.1 Triton-X100 in
PBS). Images were obtained by an inverse Olympus IX81 microscope
equipped with the corresponding ﬂuorescence system (Olympus,
Hamburg, Germany). Fluorescence within cells was measured byp-CREB
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Fig. 6. Detection of phospho-Erk1/2, phospho-ATF-1 and phospho-CREB by immunoﬂuorescen
silence AR expression. Nuclei were stainedwith DAPI andwith speciﬁc primary antibodies again
ondary antibody as detailed in “Materials andmethods”. Treatment of the GC-2 cells with 1 nM
rescence signals indicating activated Erk1/2, CREB, or ATF-1 were signiﬁcantly higher (G) after
steroid (A, C, E) (n = 19–28; means ± SEM; ** = p ≤ 0.01; scale bar = 50 μm).using the software program ImageJ (freely available at http://rsbweb.
nih.gov/ij/). All cells in the optical ﬁeld were considered. Data points
were transferred to and analyzed by the software program GraphPad
Prism4 (GraphPad Software, Inc., La Jolla, CA, USA).
2.9. Statistical analysis
Loading differences in the various western blots were corrected by
taking into consideration the optical density of unphosphorylated Erk1/
2 bands or total actin bands, detected in western blots that were run                        B)
                        F)
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AR-siRNA; 1 nM DHEAS
1 0 1
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ce after silencing AR expression by siRNA. All cells shownwere treated with oligo pair 3 to
st phospho-Erk1/2, phospho-ATF-1 or phospho-CREB and an Alexa Fluor 488-labeled sec-
DHEAS for 30 min triggered the activation of Erk1/2 (B), ATF-1 (D) and CREB (F). The ﬂuo-
30 min of incubation with 1 nM DHEAS than the signals measured in the absence of the
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Fig. 7. Western blot analysis of phospho-Erk1/2 after silencing AR expression by siRNA.
Cells were treated with control siRNA or with siRNA to silence AR expression. After
30 min of incubation in the presence or absence of 1 nM DHEAS, cell lysates were pre-
pared and probed in a western blot as described under “Materials and methods”. Incuba-
tionwith 1 nMDHEAS, which had no effect on total Erk1/2 (A), triggered the formation of
phospho-Erk1/2 independent of whether the AR had been silenced or not (B, C). The data
shown in (C) were corrected for the amount of total Erk1/2 as shown in (A) (n = 3;
means ± SEM; * = p ≤ 0.05).
3069M. Shihan et al. / Biochimica et Biophysica Acta 1833 (2013) 3064–3075in parallel. Data were analyzed by GraphPad Prism4 Software and by ap-
plying one-way ANOVAwith repeated measures and Dunnett's compari-
son of all data to the control. Signiﬁcance was accepted at p b 0.05.
3. Results
3.1. DHEAS induces activation of Erk1/2
Steroid hormones exert their non-classical actions by activating en-
zymes of signaling cascades that are usually triggered by growth factors
[15,16]. One of these is the Src/Ras/Raf/Erk1/2 signaling cascade, and
thus our ﬁrst aim was to examine whether DHEAS might induce Erk1/2
activation in GC-2 cells.
As shown in Fig. 1B, 1 nM DHEAS induced a clear activation (phos-
phorylation) of Erk1/2 that was signiﬁcant after 30 min of incubation
(Fig. 1C). When Erk1/2 activation was determined by incubating the
cells for 30 min with various concentrations of DHEAS (Fig. 1E), signiﬁ-
cant activation of Erk1/2 was obtained at DHEAS concentrations of
0.1 nM and above (Fig. 1F). Incubation with DHEAS did not affect ex-
pression of total Erk1/2 (Fig. 1A and D).
In parallel experiments we addressed the effect of DHEA on Erk1/2
activation under conditions identical to those used for the investigation
of the DHEAS effect. DHEA-induced activation was never observed in
these experiments; in fact, if anything there was a small but signiﬁcant
reduction in active Erk1/2 seen with 10 nM DHEA (see Supplementary
material). After obtaining this result, we conﬁned our further investiga-
tions to DHEAS-induced signaling.
3.2. c-Src activation by DHEAS
Steroid hormone-induced Erk1/2 activation has been shown in sev-
eral cases to be mediated by activation of c-Src [17–20] via phosphory-
lation at Tyr419. A similar mechanism is apparently involved in the
DHEAS-stimulated induction of signaling cascades in GC-2 cells: we
found that DHEAS stimulates phosphorylation of c-Src at Tyr419,
which was visualized by western blotting using a monoclonal antibody
speciﬁcally recognizing the phosphorylated form of this amino acid
(Fig. 2A). After 30 min of incubation with various concentrations of
DHEAS, signiﬁcant activation of c-Src was obtained at concentrations
of 1 nM or greater (Fig. 2B).
3.3. DHEAS-induced activation of transcription factors CREB and ATF-1
Activation of Erk1/2 leads to its translocation to the nucleus and
to subsequent activation of transcription factors. Stimulation of the
c-Src/Ras/c-Raf/Erk1/2 pathway is known to activate the transcription
factors CREB (cyclic AMP-responsive element bindingprotein) andATF-
1 (activating transforming factor-1) [16,18,21]. Since the results shown
in Fig. 1 and 2 clearly demonstrate activation of this signaling cascade,
we investigated a possible DHEAS-induced activation of ATF-1 and
CREB in the GC-2 cells. In western blots with an antibody that cross-
reacts with phospho-CREB and phospho-ATF-1,we observed signiﬁcant
activation of both transcription factors following 30 min of incubation
with 0.1 nM DHEAS (Fig. 3A–C). This response was similar to that
observed for the DHEAS-induced activation of Erk1/2 (Fig. 1F).
3.4. Lack of steroid sulfatase expression in GC-2 cells
DHEAS is often considered a pro-androgen that needs to be
desulfated to DHEA and thereafter converted to testosterone in order
to exert its androgenic properties [3]. Therefore, we examined whether
the GC-2 cells might express steroid sulfatase-speciﬁc mRNA. Sulfatase-
speciﬁc mRNA/cDNA was not detectable at all annealing temperatures
and MgCl2 concentrations used (Fig. 4A). In the same preparations
GAPDH was detectable (Fig. 4A), indicating that mRNA isolation and
its reverse transcription to cDNA had been carried out correctly and afaulty RT-PCR could not be the reason for the lack of sulfatase-speciﬁc
ampliﬁcates in extracts of GC-2 cells. The expected sulfatase-speciﬁc
ampliﬁcate of 624 bp was clearly present, however, in extracts from
mouse adrenals at an annealing temperature of 60 °C in the presence
of 2 mM MgCl2, indicating that the lack of signals in extracts of GC-2
cells was not due to ﬂawed primers (Fig. 4A).
To further conﬁrm that steroid sulfatase is not involved in the gener-
ation of DHEAS-induced signaling, we used the steroid sulfatase-speciﬁc
inhibitor STX64 and investigated the effects of DHEAS on activation of
Erk1/2 in the presence of this compound. As Fig. 4B shows, 10 nm
STX64 did not inhibit DHEAS-induced phosphorylation of Erk1/2. Total
Erk1/2 was not inﬂuenced under these conditions (Fig. 4C). The stimu-
lation of Erk1/2 phosphorylation under these conditionswas highly sig-
niﬁcant (Fig. 4D).
The implication of the experiments summarized in Fig. 4 is that
DHEAS does not exert its effects via conversion to DHEA but rather di-
rectly, by binding to a receptor in a hormone-like fashion.3.5. Does the androgen receptor mediate the DHEAS effects?
The results described in the previous paragraphs clearly showa strong
overlap betweenDHEAS-induced signaling and the non-classical action of
testosterone [16]. Thus, one can speculate on a possible involvement of
the androgen receptor in DHEAS-induced signaling. This possibility was
addressed by re-investigating DHEAS effects on Erk1/2, CREB and ATF-1
activation after silencing the AR expression by means of siRNA.
Fig. 5 shows the RT-PCR results obtained after attempting to silence
the expression of AR-speciﬁcmRNAby using 3 different oligonucleotide
pairs. It is apparent that the best result was obtained by using the third
combination of oligonucleotide primers (oligo pair 3), whose sequence
was listed under “Materials and methods”. The expression of AR-
speciﬁc mRNA was not affected by either Lipofectamine or control
siRNA (Fig. 5). Thus, for the following experiments cells were treated
with oligo pair 3.
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then subjected to a ﬁxation/immunostaining procedure as described
under “Materials andmethods” to detect thephosphorylated formsof ei-
ther Erk1/2, ATF-1, or CREB. Fig. 6 shows that treatment of the GC-2 cells
with AR-speciﬁc siRNA does not affect the DHEAS-induced activation
(phosphorylation) of Erk1/2, ATF-1 or CREB. Erk1/2 activation is seen
in the form of green ﬂuorescence that is spread over the entire volume
of DHEAS-treated cells despite the absence of AR (Fig. 6B). Activated
transcription factors ATF-1 (Fig. 6D) and CREB (Fig. 6F) are visible as
green ﬂuorescent signals within the nucleus after the exposure of the
cells to DHEAS. In the absence of DHEAS, a relatively low, basal amountA)
C)
B)
50 µm
Fig. 8. Silencing ARprotein expression by siRNA. Cellswereﬁxed inmethanol and incubat-
ed with a primary antibody against the AR and a ﬂuorescent secondary antibody (rabbit
anti-goat IgG-FITC green), as described under “Materials andmethods”. Nuclei are stained
by DAPI, as described under “Materials and methods”. (A) All control cells show green
ﬂuorescence, indicating the presence of the AR. (B)When the primary antibodywas omit-
ted, only DAPI-stained nuclei were visible, indicating that the green ﬂuorescence seen in
(A) was not due to non-speciﬁc binding of the secondary antibody. (C) When cells were
treated with siRNA to silence AR expression, AR-speciﬁc protein was not detectable by
the combination of the antibodies used in (A), indicating the successful silencing of the
AR protein. Only DAPI-stained nuclei can be seen in (B) and (C).of activated Erk1/2 (Fig. 6A), ATF-1 (Fig. 6C), or CREB (Fig. 6E) was re-
stricted to a few cells only. Total cell-associated ﬂuorescence corre-
sponding to active Erk1/2, ATF-1, or CREB was signiﬁcantly higher after
30 min of incubationwith 1 nMDHEAS than the ﬂuorescencemeasured
in the absence of the steroid (Fig. 6G; see also upper “control” panels of
Fig. 10A–C for the respective control responses to DHEAS in the absence
of any siRNA, whichwere similar to the responses shown in Fig. 6). Since
immunoﬂuorescence considers only cells residing within the optical
ﬁeld of themicroscope, we carried out an additional western blot exper-
iment in order to obtain an average for all cells in the incubationmixture.
As can be seen in Fig. 7, treatment of GC-2 cells with siRNA to silence the
expression of AR does not impair the ability of DHEAS to induce Erk1/2
activation, which is consistent with the results shown in Fig. 6A and B.
The information shown in Figs. 5, 6, and 7 indicates that the AR is not
involved in the generation of DHEAS-induced signaling. Nevertheless,
since silencing of mRNA might not necessarily lead to a rapid decrease
in the expression of the targeted protein, we investigated by immunoﬂu-
orescence whether the AR protein is still present in the cells despite the
reduction of AR-speciﬁc mRNA/cDNA by siRNA. The results of the inves-
tigation are summarized in Fig. 8. While green ﬂuorescence, indicating
the expression of the AR protein, is visible in every GC-2 cell in the
image shown in Fig. 8A, it is entirely missing when the ﬁrst antibody
against AR was omitted (Fig. 8B) or after cells were treated with siRNA
(primer pair 3) to prevent expression of AR-speciﬁc mRNA (Fig. 8C).3.6. Involvement of Gnα11 in DHEAS-induced signaling
Many hormones, among them steroid hormones, elicit their actions
through G-protein-coupled receptors (GPCRs) [22–25]. In the mast cell
line RBH-2H3 the Gq/11 protein was shown to interact with DHEAS
[26]. Although there appear to be no reports concerning the expression
of Gq/11 in the various cell types of mouse testes, Gnα11 (equivalent to
Gq/11) expression was detected in all cell types of human testes [27].
Since we determined that the AR does not participate in DHEAS-
induced signaling in GC-2 cells, and because GC-2 cells express Gnα11
mRNA (Fig. 9), we investigated a possible involvement of GPCRs in the
signaling cascade by silencing Gnα11 expression in these cells.
The RT-PCR results shown in Fig. 9 demonstrate that after
transforming GC-2 cells with the siRNA oligo pair 2 (see Materials and
methods), the expression of Gnα11-speciﬁc mRNA/cDNA is reduced
to a minimum. The expression of Gnα11-speciﬁc mRNAwas not affect-
ed by either Lipofectamine + Opti-MEMor control siRNA (Fig. 9). Oligo
pair 1 caused only a slight reduction in the expression of Gnα11-speciﬁcO
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Fig. 9. Silencing expression of Gnα11-speciﬁc mRNA/cDNA by means of siRNA. Cells
were incubated with 2 different oligonucleotide pairs (oligo pair 1 or 2) to silence Gnα11-
speciﬁc mRNA expression. Isolation of mRNA and RT-PCR were carried out as described
under “Materials and methods”. Oligonucleotide pair 2 was the most efﬁcient and was
used in all subsequent experiments to silence the expression of Gnα11 (Fig. 10 and 11).
Treatment of the cells with Opti-MEM plus Lipofectamine or Opti-MEM plus Lipofectamine
plus the control siRNA (control siRNA) did not inﬂuence Gnα11 mRNA expression.
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with oligo pair 2.
GC-2 cells treated with either control siRNA or with siRNA against
Gnα11 were incubated with 0 or 1 nM DHEAS for 30 min. Detection
of phospho-Erk1/2, phospho-ATF-1, or phospho-CREB by immunoﬂuo-
rescence was carried out as described under “Materials and methods”.
Treatment of GC-2 cells with control siRNA did not affect activation
of Erk1/2, ATF-1, or CREB by 1 nM DHEAS (Fig. 10). Total cell-
associated ﬂuorescence corresponding to active Erk1/2, ATF-1, or CREB
was signiﬁcantly higher after 30 min of incubation with 1 nM DHEAS
in cells treated with control siRNA than the ﬂuorescence measured in
the absence of the steroid. In parallel, treatment with siRNA against
Gnα11 expression leads to the complete abolition of the effects of
DHEAS, clearly demonstrating the involvement of this protein in medi-
ating DHEAS-induced signaling. Fluorescence corresponding to active
Erk1/2, ATF-1, or CREB after 30 min of incubation with 1 nM DHEASA) phospho-Erk1/2
DHEAS       0 nM
control
control siRNA
Gnα11 siRNA
Fig. 10.Detection of phospho-Erk1/2, phospho-ATF-1 and phospho-CREB by immunoﬂuorescen
vehicle only (no DHEAS). Right columns: cells received 1 nMDHEAS. Upper rows: controls (un
control siRNA. Bottom rows: cells treatedwith Lipofectamine, Opti-MEM, and siRNA to silence G
few or none of the cells showed green ﬂuorescence, indicating active Erk1/2. Control cells and
almost all cells at various intensities. DHEAS did not induce Erk1/2 activation in cells that had be
When cells were treatedwith siRNA against Gnα11, DHEAS did not induce ATF-1 activation (gr
DHEAS induced ATF-1 activation in all nuclei. (C) Detection of activated CREB. DHEAS-induced
silence Gnα11 expression. Control cells and cells treatedwith negative control siRNAdisplayed
in panels A–C. The green ﬂuorescence of all cells in the optical ﬁeld was considered (n = 70–1was at the same level as the ﬂuorescence measured in the absence of
the steroid in these Gnα11-speciﬁc siRNA-treated cells.
Thewestern blot shown in Fig. 11 conﬁrms the immunoﬂuorescence
experiments. Silencing Gnα11 expression by transforming the GC-2
cellswith oligo pair 2 leads to abolition of theDHEAS-induced activation
of Erk1/2 (Fig. 11). Treatment of the cells with the negative control
siRNA had no effect on Erk1/2 activation (Fig. 11), which at 1 nM
DHEAS occurred to the same extent as in untreated cells (Fig. 1F).
4. Discussion
Steroid hormones are known to mediate their effects by two differ-
ent mechanisms: In the so-called “classical” action of steroid hormones,
they bind to intracellular steroid hormone receptors, which function es-
sentially as ligand-activated transcription factors. Once activated, these
receptors bind toDNA and activate the expression of target genes. In the                  1 nM
200 µm
ce after silencingGnα11 expression by siRNA. (A–C) Left columns: cells were treatedwith
treated cells). Middle rows: controls treated with Lipofectamine, Opti-MEM, and negative
nα11 expression (oligo pair 2). (A) Detection of activated Erk1/2. In the absence of DHEAS,
cells treated with control siRNA responded to 1 nM DHEAS and displayed active Erk1/2 in
en treatedwith siRNA to silence the expression of Gnα11. (B) Detection of activated ATF-1.
een ﬂuorescencewithin cell nuclei). In control cells and in cells treatedwith control siRNA,
activation of CREB (green ﬂuorescence) was absent in nuclei of cells treatedwith siRNA to
active CREB in all nuclei after DHEAS treatment. (D) Statistical analysis of the results shown
70; means ± SEM; ** = p ≤ 0.01).
B) phospho-ATF-1
DHEAS       0 nM                   1 nM
control
control siRNA
Gnα11 siRNA
200 µm
Fig. 10 (continued).
3072 M. Shihan et al. / Biochimica et Biophysica Acta 1833 (2013) 3064–3075so-called “non-classical” pathway, steroid hormones bind to receptors
associated with the plasma membrane [15]. These latter receptors are
possibly localized within membrane rafts and mediate rapid activation
of intracellular signaling cascades [28],which in some cases are identical
to cascades normally activated by growth factors, such as the Src/PI3K/
Akt or the Src/Ras/Raf/Erk1/2 pathways [15,29]. While DHEA has
been shown to induce similar cascades in neuronal cells [30,31], little
is known about the action of DHEAS, especially on cells of the reproduc-
tive system, although it has been shown to be produced in rodent
gonads [32,33].
The process of spermatogenesis and the maturation of spermatogo-
nia to spermatozoa depend on the activation of Erk1/2 and other
mitogen-activated protein kinases (MAPK) [34,35], and Erk1/2 activa-
tion is an absolute requirement for the production of haploid spermato-
zoa [36,37]. Therefore, we ﬁrst investigated whether DHEAS might
induce Erk1/2 activation in a spermatogenic cell line. As shown in
Fig. 1, DHEAS induces a signiﬁcant activation (phosphorylation) of
Erk1/2 in a time- and concentration-dependent manner in GC-2 cells.
This is the ﬁrst demonstration of Erk1/2 activation by DHEAS in a cell
line derived from the reproductive system.
In accordancewith the non-classical pathway of steroid hormone re-
ceptor action, Erk1/2 activation by DHEAS is accompanied by c-Src acti-
vation via phosphorylation at Tyr419 (Fig. 2). This result showing a linkbetween c-Src and Erk1/2 activation is in good agreement with other
studies demonstrating similar effects of steroid hormones [20,38] and
suggests that DHEAS, consistent with it being a steroid hormone, trig-
gers the c-Src/Ras/c-Raf/Erk1/2 signaling cascade. In Sertoli cells, the
induction of this signaling pathway leads to the activation of the tran-
scription factor CREB [16,18] and of the CREB-related factor ATF-1
[21]. Both CREB and ATF-1 aremembers of the bZIP superfamily of tran-
scription factors and stimulate transcription when phosphorylated
either at Ser133 (CREB) or at Ser63 (ATF-1), residues localized within
a conserved region of the two proteins termed the phosphorylation
box [39]. Transcription factors like CREB or ATF-1 that bind to cAMP-
responsive element (CRE) promoters induce the transcription of a
great variety of genes.
CREB and phospho-CREB are present not only in Sertoli cells but also
in various other cells of the gonads, including spermatogonia, round
spermatids, and, as shown recently, also in elongated spermatids
[40–42]. CREB/CRE-inducible transcription is essential for the survival
of spermatocytes and the production of mature spermatozoa [43]. The
amount of phospho-CREB varies during the spermatogenic cycle [42],
which would be consistent with it being directly involved in the differ-
entiation process of germ cells.
The results summarized in Fig. 3 clearly show the DHEAS-induced
activation of both CREB and ATF-1 in the spermatogenic cell line GC-2.
C) phospho-CREB
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3073M. Shihan et al. / Biochimica et Biophysica Acta 1833 (2013) 3064–3075A signiﬁcant activation of ATF-1 (Fig. 3B) or CREB (Fig. 3C)was obtained
at DHEAS concentrations of 0.1 nM or greater, as was seen for the acti-
vation of Erk1/2 (Fig. 1F).
Although steroid sulfatase was not involved in the DHEAS-induced
activation of Erk1/2 (Fig. 4), suggesting that DHEAS is not being
converted to DHEA or testosterone to exert its effects, the fact that
DHEAS induces a signaling cascade similar to the non-classical signaling
pathway of testosterone [44] made it appear possible that the AR is in-
volved in the propagation of the DHEAS-induced signaling. Therefore,
we addressed a possible involvement of the AR in the generation of
the DHEAS-induced signaling cascade in a series of experiments by
restricting its expression at the mRNA and protein level by means of
siRNA (Fig. 5 and 8). The results summarized in Fig. 6 and 7 clearly
show that the abolition of AR does not affect the induction of the
DHEAS-induced signaling cascade that leads to activation of Erk1/2,
ATF-1, and CREB. This, together with the experiment showing the ab-
sence of steroid sulfatase, indicates that DHEAS must exert its effects
by a different pathway which does not require desulfation or AR.
We next considered what other membrane-associated hormone
receptors might mediate the observed effects of DHEAS. Owing to the
fact that GPCRs have been shown to trigger activation of Erk1/2 in var-
ious signaling cascades [45–47] and because steroid hormones oftenmediate their actions through GPCRs [22–25], we investigated a possi-
ble involvement of a receptor coupled to a G-protein in DHEAS signaling
by silencing the expression of Gnα11.
Gnα11 is a member of the Gqα family of heterotrimeric G proteins
[47]. It is ubiquitously expressed across tissues and is present also in
GC-2 cells, as shown in Fig. 9. Silencing Gnα11 expression in GC-2
cells abolished all DHEAS-induced signaling observed thus far: stimula-
tion of Erk1/2, ATF-1, and CREB was no longer detected after treatment
of the cells with Gnα11-speciﬁc siRNA, while the treatment of the cells
with the control siRNA did not inﬂuence the DHEAS-induced activation
of these enzymes and factors (Fig. 10 and 11).
The results presented here clearly indicate the involvement of a
GPCR in the action of DHEAS and support earlier ﬁndings showing the
involvement of Gq/11 in the actions of DHEAS on the mast cell-line
RBL-2H3 [26]. Nevertheless, although GPCRs have been identiﬁed or
proposed for various steroid hormones, the actual DHEAS-speciﬁc
GPCR has yet to be identiﬁed.
In summary, our investigation calls into question theheretofore gen-
erally accepted idea of DHEASbeing simply a pro-androgen and demon-
strates for the ﬁrst time that DHEAS acts as a steroid hormone on a
spermatogenic cell line and triggers the activation of a signaling cascade
that reﬂects the non-classical signaling pathway of steroid hormones
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3074 M. Shihan et al. / Biochimica et Biophysica Acta 1833 (2013) 3064–3075involvingmembrane-bound GPCRs. The identiﬁcation of the DHEAS re-
ceptor and of target mRNAs whose expression is controlled by the acti-
vation of the CRE promoters through the transcription factors CREB and
ATF-1will help to deﬁne a role of DHEAS in the physiology of cells of the
male and possibly also of the female reproduction system.
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